Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,397 across all filing types
Latest filing 2020-03-30 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Imfinzi approved in US for small cell lung cancer
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated March 30, 2020. It announces a specific corporate event: the US FDA approval of AstraZeneca's drug Imfinzi for extensive-stage small cell lung cancer, supported by Phase III CASPIAN trial data. This type of announcement, which is a material update disseminated via the Regulatory News Service (RNS) system, fits best under the general 'Regulatory Filings' category, as it is not a comprehensive financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific shareholder/board action (AGM-R, DVA, MANG). While it is a press release, the presence of the RNS header and the nature of the announcement (regulatory milestone) strongly suggest classification as a general regulatory filing/announcement.
2020-03-30 English
Farxiga CKD trial early stop for positive efficacy
Legal Proceedings Report Classification · 99% confidence The document is identified by the header 'RNS Number : 0048I' and contains a press release dated March 30, 2020, from AstraZeneca PLC. The content announces the early stopping of a Phase III clinical trial (DAPA-CKD) for the drug Farxiga due to overwhelming efficacy and states that full results will be submitted for presentation at a forthcoming medical meeting, followed by regulatory discussions. This is a specific, material announcement to the market, not a comprehensive annual report (10-K), an interim report (IR), or a general earnings release (ER). Since it is a formal announcement disseminated via the RNS system, and it details a significant corporate/clinical development that doesn't fit the other specific categories (like M&A, Dividend, or Director Dealing), it falls best under the general 'Regulatory Filings' category, which serves as a fallback for important, non-standard announcements distributed through official channels like RNS.
2020-03-30 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2020-03-26 English
LOKELMA APPROVED IN JAPAN FOR THE TREATMENT OF HYPERKALAEMIA
Foreign Filer Report
2020-03-26 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly states it is a 'Disclosure under Article 19 of the EU Market Abuse Regulation'. It details transactions (vesting of shares) by Persons Discharging Managerial Responsibilities (PDMRs) like the CEO and CFO. This type of insider transaction reporting, especially when issued via RNS, falls under regulatory disclosure concerning director dealings. The definition for Director's Dealing (DIRS) covers 'Report of personal share transactions by company directors and executives (insider trades)'. Although it is an RNS announcement, the core content is a DIRS filing.
2020-03-26 English
Lokelma approved in Japan for hyperkalaemia
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 6832H' and is dated March 26, 2020. It announces a specific corporate event: the approval of the drug Lokelma in Japan. The text concludes with contact information for RNS and a disclaimer stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure is characteristic of a general regulatory news service announcement, which falls under the 'Regulatory Filings' category (RNS) as it is a broad announcement disseminated via the official news service and does not fit the more specific categories like Earnings Release (ER), Capital Update (CAP), or Director's Dealing (DIRS). The document length (7268 chars) is substantial enough that it is not merely a placeholder for a larger report, but the content itself is a news announcement.
2020-03-26 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.